| _version_ | 1866901690974732288 |
|---|---|
| author | Cruz, Licurgo Salcedo, Abrahan Ruiz, Omarlyn Crousett, Enrique Taveras-Franco, Alvaro |
| author_facet | Cruz, Licurgo Salcedo, Abrahan Ruiz, Omarlyn Crousett, Enrique Taveras-Franco, Alvaro |
| contents | <p>Background: Advances in cancer therapy have significantly improved survival, leading to a growing population of patients at risk for treatment-related cardiovascular complications. Cardiotoxicity, which includes ventricular dysfunction, arrhythmias, and structural heart disease, has emerged as a major determinant of morbidity and mortality in oncology patients. While several risk factors have been identified, including age, comorbidities, and type of cancer therapy, most evidence derives from North American and European populations. Data from Latin America and the Caribbean remain limited, despite differences in healthcare access, cardiovascular risk profiles, and cancer epidemiology. Understanding region-specific predictors of cardiotoxicity is essential to optimize surveillance strategies and guide personalized cardio-oncology care.</p> <p>Purpose: To identify clinical and oncologic predictors of cardiotoxicity in a contemporary cardio-oncology cohort.</p> <p>Methods: We conducted a cross-sectional study of 3,211 oncology patients evaluated in a dedicated cardio-oncology clinic in the Caribbean between October 2023 and September 2025. Demographic, cardiovascular, and oncologic variables, including cancer type, were analyzed. Cardiotoxicity was defined as ventricular dysfunction, arrhythmia, or structural abnormalities attributable to cancer therapy. Results: Among 3,211 patients (mean age 58.1 ± 14.9 years; 65.7% female), breast cancer was the most common malignancy (43%), followed by colorectal (10%) and lung cancer. Cardiotoxicity was observed in 15.8% of patients. A higher prevalence was noted in men compared with women (22.4% vs 12.1%; p<0.01) and in patients with type 2 diabetes mellitus (28.7% vs 13.5%; p<0.01). Breast cancer patients represented the largest proportion of cardiotoxicity cases, consistent with exposure to cardiotoxic therapies.</p> <p>Conclusion: In this Caribbean cardio-oncology cohort, cardiotoxicity affected approximately one in six patients and was more frequent among men and those with diabetes. These findings highlight the importance of risk-based cardiovascular surveillance and support the development of region-specific cardio-oncology strategies.</p> |
| format | Recurso digital |
| id | zenodo_https___doi_org_10_5281_zenodo_18795620 |
| institution | Zenodo |
| language | |
| publishDate | 2026 |
| publisher | Zenodo |
| record_format | zenodo |
| spellingShingle | Clinical predictors of cardiotoxicity in a large cardio-oncology cohort: a caribbean registry analysis Cruz, Licurgo Salcedo, Abrahan Ruiz, Omarlyn Crousett, Enrique Taveras-Franco, Alvaro Cardio-Oncology Breast cancer Colorectal Neoplasms <p>Background: Advances in cancer therapy have significantly improved survival, leading to a growing population of patients at risk for treatment-related cardiovascular complications. Cardiotoxicity, which includes ventricular dysfunction, arrhythmias, and structural heart disease, has emerged as a major determinant of morbidity and mortality in oncology patients. While several risk factors have been identified, including age, comorbidities, and type of cancer therapy, most evidence derives from North American and European populations. Data from Latin America and the Caribbean remain limited, despite differences in healthcare access, cardiovascular risk profiles, and cancer epidemiology. Understanding region-specific predictors of cardiotoxicity is essential to optimize surveillance strategies and guide personalized cardio-oncology care.</p> <p>Purpose: To identify clinical and oncologic predictors of cardiotoxicity in a contemporary cardio-oncology cohort.</p> <p>Methods: We conducted a cross-sectional study of 3,211 oncology patients evaluated in a dedicated cardio-oncology clinic in the Caribbean between October 2023 and September 2025. Demographic, cardiovascular, and oncologic variables, including cancer type, were analyzed. Cardiotoxicity was defined as ventricular dysfunction, arrhythmia, or structural abnormalities attributable to cancer therapy. Results: Among 3,211 patients (mean age 58.1 ± 14.9 years; 65.7% female), breast cancer was the most common malignancy (43%), followed by colorectal (10%) and lung cancer. Cardiotoxicity was observed in 15.8% of patients. A higher prevalence was noted in men compared with women (22.4% vs 12.1%; p<0.01) and in patients with type 2 diabetes mellitus (28.7% vs 13.5%; p<0.01). Breast cancer patients represented the largest proportion of cardiotoxicity cases, consistent with exposure to cardiotoxic therapies.</p> <p>Conclusion: In this Caribbean cardio-oncology cohort, cardiotoxicity affected approximately one in six patients and was more frequent among men and those with diabetes. These findings highlight the importance of risk-based cardiovascular surveillance and support the development of region-specific cardio-oncology strategies.</p> |
| title | Clinical predictors of cardiotoxicity in a large cardio-oncology cohort: a caribbean registry analysis |
| topic | Cardio-Oncology Breast cancer Colorectal Neoplasms |
| url | https://doi.org/10.5281/zenodo.18795620 |